On July 14, 2026, the Federal Trade Commission announced a proposed consent settlement with Caremark Rx and its rebate-aggregating affiliate Zinc Health Services, resolving the antitrust case that alleged the pharmacy benefit manager’s (PBM) formulary and rebating practices inflated insulin list prices. The FTC estimates the order will lock in up to $8.5 billion in consumer savings over ten years and unlock as much as $4.5 billion more through point-of-sale rebates over the same period. It is the second of three expected PBM resolutions, following the Express Scripts consent decree in February, with Optum still in talks.
The trade coverage frames this as an insulin-affordability and antitrust-precedent story. For a self-funded health plan, that framing buries the lede. The settlement’s structural terms are not confined to insulin: Caremark must stop preferring high-list-price (high-WAC, or wholesale acquisition cost) drugs over economically preferable low-WAC alternatives on its standard formulary, and must move a meaningful share of negotiated rebate value to the point of sale. Those two levers move net-of-rebate drug cost, which is the single largest swing factor in the pharmacy expected claim ratio (ECR). This is a reserve event, not a headline about a diabetes drug.
Who it affects
The exposure sits with self-insured employers, public-entity plans, university and hospital health plans, and the Taft-Hartley funds that contract with CVS Caremark or Zinc for pharmacy administration. Caremark is the largest of the big three PBMs by covered lives, so the reach is broad. Plans that book pharmacy claims gross and accrue an expected rebate receivable, which is most self-funded plans, carry the effect directly on the balance sheet. Stop-loss buyers feel it a step later, because pharmacy claims that pierce a specific attachment are typically measured on a paid, often gross, basis that the settlement now scrambles.
The reserve mechanism: level and timing both move
Pharmacy IBNR has a structural quirk that medical IBNR does not. Medical claims develop on a fairly stable paid pattern. Pharmacy claims settle almost immediately at the point of sale, so the “incurred but not reported” piece is small; the real estimation problem is the rebate. A plan pays roughly gross at the counter, then waits one to two quarters for the PBM to reconcile and remit rebate dollars. The gross-to-net gap on rebated brands can run 40% to 60% of list, and on insulin it has historically run higher. That gap is not a claim lag; it is a receivable lag, and it distorts pharmacy reserving in two directions at once.
First, the level. Point-of-sale rebating lowers what the member and the plan pay at the counter while shrinking the back-end rebate receivable. Net cost per script on affected drugs falls, which pulls down the pharmacy ECR. But the plan that keeps its old gross-to-net assumption will over-accrue rebate income it will no longer receive on the back end, because that value now arrives as a lower upfront price instead. The net trend improves; the accrual mechanics that estimate it do not, unless someone resets them.
Second, the timing. Moving rebate value to the point of sale compresses the rebate accrual lag. A plan that has calibrated its pharmacy IBNR to a two-quarter rebate emergence pattern is modeling a development curve that the settlement is flattening. This is the Sixth Circuit PBM reasoning and the CAA-2026 full rebate pass-through mandate working in the same direction: less rebate value trapped downstream, more of it visible at the transaction. The reserve risk is booking a receivable against a rebate that has already been delivered as a lower price, effectively double-counting the discount.
Where this shows up in your reserves
Open the pharmacy line of your latest actuarial report and find the net-paid-to-gross-paid ratio by plan year. That ratio is your embedded gross-to-net assumption, and it is the number the settlement moves. On the balance sheet, the estimated rebate receivable sits as a contra to pharmacy claims payable; watch whether that receivable is growing while cash remittances flatten, the classic sign that the accrual assumption is stale against a compressing lag. On the stop-loss reconciliation, check whether specific-claim accumulators are measured gross or net of rebate. If pharmacy severity is measured gross while net trend is falling, your modeled attachment probability drifts away from reality: fewer claimants truly pierce a fixed specific deductible once net drug cost declines, even as utilization holds.
Why the pattern matters
One settlement is an event; three converging consent decrees are a repricing. Express Scripts in February, Caremark in July, and a likely Optum resolution would cover the vast majority of self-funded covered lives. If the three orders settle on a common point-of-sale rebate structure, plans gain something they have never had: a net drug price they can actually model prospectively rather than reconcile in arrears. That is a durable shift in the pharmacy ECR baseline, layered on top of the DOL’s July 1 ERISA 408(b)(2) PBM fee-disclosure enforcement, which forces the compensation data needed to true up the accrual in the first place.
What this means for your next review
Do not let the pharmacy line ride on last year’s gross-to-net assumption. Ask your actuary to re-derive the net-of-rebate ECR under a point-of-sale rebate scenario and to re-fit the rebate emergence lag, then flow the revised net trend into your stop-loss attachment analysis before renewal. The lower net trend is real, but it only reaches the bottom line if the reserve mechanics stop accruing a receivable the settlement has already delivered as price. See IBNR for self-funded health plans for how the rebate lag sits inside the estimate, and what’s driving your IBNR higher for the offsetting utilization pressures that can mask a falling unit cost.
Decision-maker checklist (next 30 to 90 days)
- Confirm whether your plan books pharmacy claims gross with a rebate receivable, or net, and document the current gross-to-net assumption by plan year.
- Ask your PBM whether your contract falls under the Caremark or Zinc structural terms and, if so, the effective date for point-of-sale rebating.
- Have your actuary re-fit the rebate accrual lag and restate the pharmacy ECR under a compressed-lag, point-of-sale scenario.
- Check whether your stop-loss specific accumulators measure pharmacy claims gross or net of rebate, and reconcile the basis with your carrier before renewal.
- Verify you are not accruing a back-end rebate receivable against value now delivered as a lower point-of-sale price.
An independent reserve review brings a second pair of eyes that’s free of the TPA’s or fronting carrier’s incentive structure. We’re working on a directory of independent reviewing actuaries. If you’d like to be considered, get in touch.
Sources
- FTC press release, “FTC Secures Major Settlement with Caremark, Resolving Antitrust Case Against Second Drug Middleman,” July 14, 2026: https://www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark-resolving-antitrust-case-against-second-drug-middleman
- FTC case docket, “Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin)”: https://www.ftc.gov/legal-library/browse/cases-proceedings/caremark-rx-zinc-health-services-et-al-matter-insulin-timeline-item-2026-07-01
- DOL Employee Benefits Security Administration, ERISA 408(b)(2) service-provider disclosure framework: https://www.dol.gov/agencies/ebsa
- Mondaq, “FTC Reaches Second Insulin Pricing Settlement: Comparing The Caremark And ESI Orders,” July 2026: https://www.mondaq.com/unitedstates/consumer-law/1819560/ftc-reaches-second-insulin-pricing-settlement-comparing-the-caremark-and-esi-orders